Loading clinical trials...

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT03478787•AbbVie

View on ClinicalTrials.gov

Summary

The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Eligibility

Age

18 - No limit years

Sex

All

Healthy Volunteers

Inclusion Criteria

•Diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the Baseline Visit
•Subject has stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis
•Subject must be a candidate for systemic therapy as assessed by the investigator;
•Subject must be an acceptable candidate to receive secukinumab according to the local label for this compound.

Exclusion Criteria

•History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis; or active skin disease other than psoriasis that could interfere with the assessment of psoriasis;
•Chronic infections including HIV, viral hepatitis (hepatitis B, hepatitis C), and/ or active tuberculosis. Subjects with a positive QuantiFERON®-TB/purified protein derivative (PPD) test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines.
•Active systemic infection during the last 2 weeks prior to Baseline Visit (exception: common cold)
•History of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix
•Previous exposure to risankizumab
•Previous exposure to secukinumab

Locations (61)

Advanced Research Associates - Glendale /ID# 204335

Glendale, Arizona, United States

Alliance Dermatology and MOHs /ID# 204336

Phoenix, Arizona, United States

Bakersfield Derma & Skin Cance /ID# 202115

Bakersfield, California, United States

Center for Dermatology Clin Res /ID# 202116

Fremont, California, United States

Dermatology Res. Assoc., CA /ID# 202170

Los Angeles, California, United States

UC Davis Health /ID# 202263

Sacramento, California, United States

Medderm Associates /ID# 202162

San Diego, California, United States

UConn Health Main /ID# 201745

Farmington, Connecticut, United States

Tory P Sullivan, MD PA /ID# 202177

North Miami Beach, Florida, United States

Renstar Medical Research /ID# 202113

Ocala, Florida, United States

Key Dates

Start Date

May 8, 2018

Primary Completion Date

July 8, 2020

Completion Date

July 8, 2020

Last Updated

July 13, 2021

Enrollment

327

ACTUAL participants

Conditions

Psoriasis

Interventions

risankizumab

DRUG

secukinumab

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 13, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments